Skip to content

Adaptive Biotechnologies

US · ADPT #2184 by market cap Listed 2019
27.93 -0.12 -0.43%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions increased by 18 in the most recent period (2026/Q3).
  • Total institutional ownership rose 2.6 percentage points.

Ownership vs. money flow

Diverging

Institutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
102.60% +2.63pp
Institutions
391 +18
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund69.63%
Hedge Fund26.51%
Individual/Insider2.54%
Public Company2.49%
Private Company1.68%
Insurance Company0.88%
VC/PE Fund0.75%
Government Pension Fund0.36%
Bank/Investment Bank0.16%

Top holders as of 2026-06-30

Viking Global Investors LP 18.53% · 29.99M sh
BlackRock 9.45% · 15.30M sh
Vanguard Capital Management, LLC 3.98% · 6.44M sh
Wellington Management Group 3.65% · 5.91M sh
Vanguard Portfolio Management, LLC 3.24% · 5.24M sh
D. E. Shaw & Co., L.P. 2.86% · 4.63M sh
T. Rowe Price Group, Inc. 2.75% · 4.44M sh
Westfield Capital Management Company, L.P. 2.64% · 4.27M sh
Geode Capital Management, LLC 2.30% · 3.72M sh
State Street Global Advisors 2.20% · 3.56M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 0 buys · 50 sells

NameRoleStake
Viking Global Investors LP -- 18.53%
Chad Robins Chairperson & CEO 0.94%
Harlan Robins Co-Founder & Former Chief Scientific Officer 0.50%
Susan Bobulsky Chief Commercial Officer of MRD 0.24%
Julie Rubinstein President 0.23%
Kyle Piskel VP, CFO & Principal Accounting Officer 0.16%
Francis Lo Chief Human Resources Officer 0.14%
Sharon Benzeno Chief Commercial Officer of Immune Medicine 0.14%
Peter Neupert Lead Independent Director 0.08%
Katey Owen Independent Director 0.04%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-12 Julie Rubinstein President Derivative Exercise and Sale -35,228 $12.14–31.22
2026-11-10 Chad Robins Chairperson & CEO Intent to Sell (Form 144) -73,221 $29.94
2026-11-10 Susan Bobulsky Chief Commercial Officer of MRD Automatic Disposition -1,875 $32.00
2026-11-09 Julie Rubinstein President Derivative Exercise and Sale -23,762 $12.14–30.58
2026-11-08 Chad Robins Chairperson & CEO Other Disposition -100,000 --
2026-11-05 Julie Rubinstein President Derivative Exercise and Sale -35,643 $12.14–27.88
2026-11-02 Julie Rubinstein President Derivative Exercise and Sale -35,643 $12.14–27.45
2026-10-28 Julie Rubinstein President Derivative Exercise and Sale -35,643 $12.14–28.90
2026-10-25 Julie Rubinstein President Derivative Exercise and Sale -35,643 $12.14–26.30
2026-10-20 Julie Rubinstein President Derivative Exercise and Sale -35,643 $12.14–25.57
2026-10-15 Julie Rubinstein President Derivative Exercise and Sale -35,643 $12.14–25.82
2026-10-12 Julie Rubinstein President Derivative Exercise and Sale -35,643 $12.14–26.41
2026-10-07 Julie Rubinstein President Derivative Exercise and Sale -35,643 $12.14–30.53
2026-10-05 Susan Bobulsky Chief Commercial Officer of MRD Automatic Disposition -6,444 $30.00
2026-10-04 Julie Rubinstein President Derivative Exercise and Sale -35,643 $12.14–29.67
2026-09-30 Julie Rubinstein President Intent to Sell (Form 144) -379,777 $28.90
2026-09-30 Francis Lo Chief Human Resources Officer Derivative Exercise and Sale -26,792 $3.99–28.61
2026-09-15 Francis Lo Chief Human Resources Officer Automatic Disposition -9,846 $28.02–28.57
2026-09-15 Francis Lo Chief Human Resources Officer Derivative Exercise and Sale -105,560 $3.99–28.02
2026-09-14 Susan Bobulsky Chief Commercial Officer of MRD Automatic Disposition -1,195 $27.00

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 20:02:38 · For reference only, not investment advice and not tailored to your situation.

Adaptive Biotechnologies discussion 0 comments

Add a comment